Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regulus (RGLS)
NASDAQ:RGLS
Regulus (RGLS) Stock Price & Analysis
393 Followers
RGLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.76 - $2.14
Previous Close$1.44
Volume12.00K
Average Volume (3M)23.16K
Market Cap
$28.11M
Enterprise Value$695.51K
Total Cash (Recent Filing)$30.78M
Total Debt (Recent Filing)$3.37M
Price to Earnings (P/E)-0.9
Beta0.80
Next Earnings
Mar 06, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding20,222,672
10 Day Avg. Volume18,393
30 Day Avg. Volume23,164
Standard Deviation0.27
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$7.67Price Target Upside447.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Regulus News
Ownership Overview
32.15% Insiders
20.05% Mutual Funds
8.21% Other Institutional Investors
39.59% Public Companies and
Individual Investors
RGLS FAQ
What was Regulus’s price range in the past 12 months?
Regulus lowest stock price was $0.76 and its highest was $2.14 in the past 12 months.
What is Regulus’s market cap?
Currently, no data Available
When is Regulus’s upcoming earnings report date?
Regulus’s upcoming earnings report date is Mar 06, 2024 which is in 87 days.
How were Regulus’s earnings last quarter?
Regulus released its earnings results on Nov 09, 2023. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.397 by -$0.003.
Is Regulus overvalued?
According to Wall Street analysts Regulus’s price is currently Undervalued.
Does Regulus pay dividends?
Regulus does not currently pay dividends.
What is Regulus’s EPS estimate?
Regulus’s EPS estimate is -$0.4.
How many shares outstanding does Regulus have?
Regulus has 20,222,672 shares outstanding.
What happened to Regulus’s price movement after its last earnings report?
Regulus reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.397. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Regulus?
Currently, no hedge funds are holding shares in RGLS
---
Regulus Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.01%
12-Months-Change
Fundamentals
Return on Equity
-84.71%
Trailing 12-Months
Asset Growth
-27.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Regulus
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
---
Top 5 ETFs holding RGLS
Vanguard Total Stock Market ETF
$200.94K
iShares Core S&P Total U.S. Stock Market ETF
$64.35
Up to five ETFs with an Outperform Smart Score that hold RGLS. The ETFs are listed according to market value of RGLS within the ETF
---